CCB Portal Please support MJHS Institute
Facebook Twitter YouTube LinkedIn

Interprofessional Webinar Series:
Palliative Care in ALS

This webinar is presented in collaboration with the
National Hospice and Palliative Care Organization.

Funding Disclosure: No commercial funding has been accepted for the activity.

Date and Time: August 4, 2016, 12:30 PM – 1:30 PM ET (Live)

Location: Online at http://www.mjhspalliativeinstitute.org/e-learning/

Speaker Name and Title:
Mara Lugassy, MD
Hospice Medical Director
MJHS Hospice and Palliative Care
New York, NY

Purpose: The purpose of this webinar is to enhance knowledge of the role of palliative care in managing amyotrophic lateral sclerosis (ALS) throughout the course of the disease.

Why Do I Need to Know This? ALS is a disease that has a profound impact on patients, families and caregivers in multiple domains. Ability to effectively manage disease-related symptoms, facilitate complex goals of care discussions, and coordinate caregiver resources are all essential to providing effective palliative care in ALS.

Objectives:
Participants will be able to:

  1. Identify an interdisciplinary approach to management of symptoms that commonly occur in ALS.
  2. Describe strategies for disease-specific goals of care discussions regarding artificial nutrition and hydration and mechanical ventilation.
  3. Identify resources to maximize patient and family support and to facilitate coordination of care throughout the disease course.

Target Audience: palliative care specialists, pain specialists, primary care providers, nurse practitioners, registered nurses, advanced practice nurses, registered nurses with a specialty in palliative care/hospice, pharmacists, allied health professionals, fellows, residents, and medical students.

Criteria for Successful Completion:

  1. Attendance at entire session (mandatory for nurses and social workers)
  2. Submission of completed evaluation form (mandatory to receive CE/CME credit for MDs, nurses, social workers)
  3. Successful completion of a posttest; 80% passing grade (mandatory to receive CE credit for social workers)

Continuing Education Credits: 1.0

Continuing Education Accreditation:

Physicians: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Hospice and Palliative Care Organization (NHPCO) and MJHS. NHPCO is accredited by the ACCME to provide continuing medical education for physicians.

NHPCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: NHPCO is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

NHPCO designates this live activity for a maximum of 1.0 contact hour. Nurses should claim only the contact hours commensurate with the extent of their participation in the activity. Accredited status by ANCC refers only to continuing nursing education and does not imply endorsement of any commercial product discussed in conjunction with this activity.

Social Workers: NHPCO is an approved provider of continuing education contact hours by the National Association of Social Workers (Provider #886414158).

This educational activity has been submitted for approval for 1.0 hours.

MJHS Institute for Innovation in Palliative Care SW CPE is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #0242.

Fees:
Individual: $25 (includes CME/CE certificate)
Group: $65 + $5 per CME/CE certificate

Registration fees for webinars are not refundable.

System Requirements for Computers and Mobile Devices:
http://support.citrixonline.com/en_US/Webinar/help_files/G2W010003

Disclosures

Mara Lugassy, MD, has no financial arrangements or affiliations with any commercial entities whose products, research or services may be discussed in these materials. Any discussion of investigational or unlabeled uses of a product will be identified.

Russell K. Portenoy, MD, Planner, has indicated a relationship with Pfizer Inc. for research grant support.

No other Planning Committee Member has any disclosures.

Planning Committee Members
Barbara Bouton, MA, FT
Colleen Fleming-Damon, PhDc, APRN-BC, ACHPN-BC, C.T.
Steven R. Gardner, MPA, PAHM
Myra Glajchen, DSW
Jennifer Kennedy, RN, MA, BSN, CHC
Russell K. Portenoy, MD
Karen Richards, PhD, EdS
Judith A. Skretny